JP2023540025A5 - - Google Patents
Info
- Publication number
- JP2023540025A5 JP2023540025A5 JP2023513278A JP2023513278A JP2023540025A5 JP 2023540025 A5 JP2023540025 A5 JP 2023540025A5 JP 2023513278 A JP2023513278 A JP 2023513278A JP 2023513278 A JP2023513278 A JP 2023513278A JP 2023540025 A5 JP2023540025 A5 JP 2023540025A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- seq
- amino acid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070440P | 2020-08-26 | 2020-08-26 | |
| US63/070,440 | 2020-08-26 | ||
| PCT/IB2021/057802 WO2022043900A1 (en) | 2020-08-26 | 2021-08-26 | Stable formulations comprising a bispecific egfr/c-met antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540025A JP2023540025A (ja) | 2023-09-21 |
| JP2023540025A5 true JP2023540025A5 (https=) | 2024-09-02 |
Family
ID=80352835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513278A Pending JP2023540025A (ja) | 2020-08-26 | 2021-08-26 | 二重特異性ｅｇｆｒ／ｃ－ｍｅｔ抗体を含む安定な製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220064307A1 (https=) |
| EP (1) | EP4204456A4 (https=) |
| JP (1) | JP2023540025A (https=) |
| KR (1) | KR20230057400A (https=) |
| CN (1) | CN116194485A (https=) |
| AR (2) | AR123340A1 (https=) |
| AU (1) | AU2021333882A1 (https=) |
| BR (1) | BR112023003373A2 (https=) |
| CA (1) | CA3192630A1 (https=) |
| CR (1) | CR20230102A (https=) |
| EC (1) | ECSP23013655A (https=) |
| IL (1) | IL300895A (https=) |
| JO (1) | JOP20230040A1 (https=) |
| MX (1) | MX2023002367A (https=) |
| PE (1) | PE20231370A1 (https=) |
| TW (1) | TWI907491B (https=) |
| WO (1) | WO2022043900A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
| WO2024003837A1 (en) | 2022-06-30 | 2024-01-04 | Janssen Biotech, Inc. | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
| AU2024287954A1 (en) * | 2023-07-07 | 2026-01-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Egfr/c-met bispecific binding protein and use thereof |
| WO2025079020A1 (en) | 2023-10-12 | 2025-04-17 | Janssen Biotech, Inc. | First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer |
| CN121045388A (zh) * | 2024-05-30 | 2025-12-02 | 英百瑞(杭州)生物医药有限公司 | 针对人c-Met和人EGFR的双特异性抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| JP2020535181A (ja) * | 2017-09-29 | 2020-12-03 | ヤンセン バイオテツク，インコーポレーテツド | 低用量抗体組成物を安定化する新規製剤 |
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
-
2021
- 2021-08-24 TW TW110131219A patent/TWI907491B/zh active
- 2021-08-24 AR ARP210102390A patent/AR123340A1/es unknown
- 2021-08-26 IL IL300895A patent/IL300895A/en unknown
- 2021-08-26 EP EP21860689.5A patent/EP4204456A4/en active Pending
- 2021-08-26 CR CR20230102A patent/CR20230102A/es unknown
- 2021-08-26 JP JP2023513278A patent/JP2023540025A/ja active Pending
- 2021-08-26 WO PCT/IB2021/057802 patent/WO2022043900A1/en not_active Ceased
- 2021-08-26 KR KR1020237009728A patent/KR20230057400A/ko active Pending
- 2021-08-26 CA CA3192630A patent/CA3192630A1/en active Pending
- 2021-08-26 MX MX2023002367A patent/MX2023002367A/es unknown
- 2021-08-26 PE PE2023000717A patent/PE20231370A1/es unknown
- 2021-08-26 AU AU2021333882A patent/AU2021333882A1/en active Pending
- 2021-08-26 CN CN202180052293.6A patent/CN116194485A/zh active Pending
- 2021-08-26 US US17/412,346 patent/US20220064307A1/en active Pending
- 2021-08-26 BR BR112023003373A patent/BR112023003373A2/pt unknown
- 2021-11-15 AR ARP210103156A patent/AR124067A2/es unknown
-
2023
- 2023-02-23 JO JOJO/P/2023/0040A patent/JOP20230040A1/ar unknown
- 2023-02-24 EC ECSENADI202313655A patent/ECSP23013655A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540025A5 (https=) | ||
| JP2024544523A5 (https=) | ||
| KR102397713B1 (ko) | 안정한 액체 약제학적 제제 | |
| FI4249512T3 (fi) | Stabiili vasta-aineformulaatio | |
| JP2024514344A5 (https=) | ||
| CN106999581A (zh) | 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型 | |
| JP2022532927A5 (https=) | ||
| MX2015002411A (es) | Formulaciones de anticuerpos y proteinas. | |
| MX2008012295A (es) | Formulacion de un anticuerpo monoclonal humano anti-igf-1r. | |
| JP2022036932A5 (https=) | ||
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| CN114762678B (zh) | 抗tigit抗体药物组合物及其用途 | |
| JP2024515968A5 (https=) | ||
| JP2024506940A5 (https=) | ||
| CN113797333A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| CL2024000232A1 (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| JP2025500784A5 (https=) | ||
| JP2022519796A5 (https=) | ||
| JP2024538140A5 (https=) | ||
| JP2022519796A (ja) | 抗ｐｃｓｋ９抗体を含む安定製剤 | |
| AU2020263318A1 (en) | The use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations | |
| RU2025126086A (ru) | Композиции, содержащие биспецифическое антитело к gprc5d/cd3 | |
| CA3182940A1 (en) | An improved process of storing and preparing the protein formulation | |
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| CN119258013A (zh) | 包含抗α4β7抗体的药物制剂 |